Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents

Respiratory Medicine
M S NiedermanR Perroncel

Abstract

Haemophilus influenzae is the most common bacterial pathogen associated with acute exacerbations of chronic bronchitis (AECB). This study determined the rate of bacterial eradication of H. influenzae during AECB treated with either macrolides or moxifloxacin. Adult AECB patients with H. influenzae were included in a pooled analysis of four double-blind, multicentre, randomised trials. Patients received either moxifloxacin (400 mg qd for 5-10 days) or macrolides (azithromycin 500 mg/250 mg qd for 5 days or clarithromycin 500 mg bid for 5-10 days). Bacterial eradication and clinical success were recorded at the test-of-cure visit (7-37 days post-therapy). Of 2555 patients in the intent-to-treat population, 910 were microbiologically valid and 292 (32%) had H. influenzae cultured at baseline. Bacterial eradication of H. influenzae was significantly higher with moxifloxacin vs. macrolide-treated patients (93.0% [133/143] vs. 73.2% [109/149], respectively, P = 0.001). Moxifloxacin also demonstrated higher eradication rates compared with azithromycin (96.8% vs. 84.6%, P = 0.019) and clarithromycin (90.1% vs. 64.2%, P = 0.001) analysed separately. Clinical success was 89.5% (128/143) for moxifloxacin vs. 85.2% (127/149) for the macrol...Continue Reading

References

May 29, 1998·American Journal of Respiratory and Critical Care Medicine·N SolerR Rodriguez-Roisin
Nov 3, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S ChodoshS Kowalsky
May 13, 1999·Clinical Therapeutics·M S NiedermanR Popovian
Dec 26, 2001·The Journal of Antimicrobial Chemotherapy·P BallUNKNOWN Consensus Group on Resistance and Prescribing in Respiratory Tract Infection
Aug 16, 2002·The New England Journal of Medicine·Sanjay SethiTimothy F Murphy
Jan 21, 2003·Emerging Infectious Diseases·W Michael Scheld
Feb 14, 2003·Journal of Chemotherapy·C GrassiUNKNOWN SMART Study Group. Studio Multicentrico con Moxifloxacina nel Trattamento delle Riacutizzazioni de Bronchite Cronica
Aug 20, 2003·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·M E JonesD F Sahm
Aug 29, 2003·Canadian Respiratory Journal : Journal of the Canadian Thoracic Society·Meyer S BalterUNKNOWN Canadian Infectious Disease Society
Nov 5, 2003·American Journal of Respiratory and Critical Care Medicine·Sanjay SethiTimothy F Murphy
Nov 14, 2003·Journal of Managed Care Pharmacy : JMCP·Michael T HalpernJordana K Schmier
Jan 17, 2004·Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-Head and Neck Surgery·Jack B AnonUNKNOWN Sinus And Allergy Health Partnership
Apr 27, 2005·Archives of Internal Medicine·Antoni RosellAntoni Torres

❮ Previous
Next ❯

Citations

May 3, 2014·International Journal of Antimicrobial Agents·Hartmut M Lode
Nov 5, 2013·Journal of Women's Health·Elisa Chilet-RosellMa Angeles Pardo
Apr 7, 2010·International Journal of Chronic Obstructive Pulmonary Disease·Marc MiravitllesUNKNOWN EVOCA Study Group
Sep 11, 2009·The Journal of Antimicrobial Chemotherapy·Gavin D Barlow, UNKNOWN BSAC Council
Dec 30, 2006·International Journal of Antimicrobial Agents·Wanchai TreyaprasertHartmut Derendorf
Jun 24, 2008·Expert Opinion on Pharmacotherapy·Marc Miravitlles, Antonio Anzueto
Nov 3, 2009·Therapeutic Advances in Respiratory Disease·Marc MiravitllesKathrin Stauch
Aug 1, 2008·Expert Review of Respiratory Medicine·Hartmut M Lode, Malina Schmidt-Ioanas
May 19, 2010·Expert Review of Respiratory Medicine·Timothy E Albertson, Andrew L Chan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.